Skip to content
Science
Our Science
Autoimmunity
P140
Type M & Diagnostic
Type 1 Diabetes
Kapiglucagon
Anti-infectives
BioAMB
BioCIN
Pipeline
Company
Mission
About Us
Our Team
ImmuPharma Biotech
Investors
Investors
AIM Rule 26 Information
Regulatory News
Corporate Governance
Board of Directors
Annual Reports
Advisers
Email Alert
Updates
Announcements
Interviews
In the Media
Contact
TR1 from Lanstead – Major interest in shares
Feb 22, 2025
TR-1: S
tandard form for notification of major holdings from Lanstead
To download form
click here
←
Previous:
Proactive
Next:
ImmuPharma proves unique Mechanism of Action of P140
→
